No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.
Division of Hematology, Oncology and Stem Cell Transplantation, University Clinic Department of Internal Medicine I, 79106, Freiburg, Germany, hartmut.bertz@uniklinik-freiburg.de.
Hartmut
H
Bertz
Kathrin
K
Drognitz
Michael
M
Lübbert
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D019411:Clinical Laboratory Techniques / Q000191:economics; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016469:Fungemia / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D014230:Triazoles / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D055815:Young Adult
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole; D015725:Fluconazole